These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35478274)

  • 1. Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.
    Bose CK
    Med Oncol; 2022 Apr; 39(5):67. PubMed ID: 35478274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
    Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.
    Kang YJ; O'Haire S; Franchini F; IJzerman M; Zalcberg J; Macrae F; Canfell K; Steinberg J
    Sci Rep; 2022 Nov; 12(1):20495. PubMed ID: 36443366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current Status and Challenges in Tumor Agnostic Treatment].
    Komine K
    Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of tissue-agnostic approvals for patients with sarcoma.
    Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
    Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
    Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
    Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
    Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
    J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
    Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
    Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions.
    Dasanu CA; Alani M; Habibi S; Codreanu I
    J Oncol Pharm Pract; 2023 May; ():10781552231178293. PubMed ID: 37246506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving landscape of tissue-agnostic therapies in precision oncology.
    Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
    CA Cancer J Clin; 2024 May; ():. PubMed ID: 38814103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
    Duffy MJ; Crown J
    Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing.
    Saeed OAM; Mann SA; Luchini C; Huang K; Zhang S; Sen JD; Piredda ML; Wang M; Baldrige LA; Sperling RM; Curless KL; Cheng L
    Hum Pathol; 2021 Sep; 115():10-18. PubMed ID: 34052294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
    André T; Cohen R; Salem ME
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
    Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
    Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.